| Actelion receives AGM agenda item requests |
| 17.03.11 15:41 | |
|
ALLSCHWIL/BASEL, SWITZERLAND - 17 March 2011 - Actelion Ltd (SIX: ATLN) reports today that Elliott Advisors (UK) Ltd has filed requests to put several items on the agenda for the shareholders' Annual General Meeting (AGM) on 05 May 2011 in Basel, Switzerland. Actelion's Board of Directors takes note of these requests and will provide shareholders with the full list of agenda items and recommendations in due course. Actelion encourages shareholders to exercise their voting rights at the AGM. The registration of shares is not mandatory under Swiss law. Shares are therefore not automatically registered in the Actelion Share Register. In order to vote on the proposals, the shares must be registered in the Share Register by 28 April 2011 at the latest. For details please visit the Actelion corporate website under: http://www.actelion.com/en/investors/events/agm/index.page Actelion Ltd. Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). |
| < Prev | Next > |
|---|